In 600 treatment-naive adults with HIV in South Africa, doravirine/lamivudine/TDF was non-inferior to dolutegravir/emtricitabine/TAF for viral suppression at 48 weeks (89.0% vs 90.7%), with less weight gain (median 3.0 vs 5.0 kg) but greater hip and spine bone loss.
RCTn = 600
Woods et al. Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial